Collecting data on patients with low-grade ovarian or peritoneal tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to gather comprehensive data on approximately 1600 female patients diagnosed with low-grade ovarian or peritoneal tumors. It focuses on collecting both prospective and retrospective information regarding disease characteristics, treatment regimens, and patient outcomes. The data will be organized in a secure repository to facilitate future research and improve understanding of these tumor types. Additionally, tumor samples will be collected to establish a tumor bank for further analysis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients whose disease progressed to a higher-grade carcinoma since the time of original diagnosis:

  * Ovarian tumor of low malignant potential
  * Low-grade serous carcinoma of the ovary
  * Primary peritoneal tumor of low malignant potential
  * Low-grade serous carcinoma of the peritoneum
  * Psammocarcinoma

Where it's running

• M D Anderson Cancer Center
  Houston, Texas, United States Recruiting

Study contacts

• Principal investigator: David M Gershenson — M.D. Anderson Cancer Center
• Study coordinator: Lisa Nathan
• Email: lcnathan@mdanderson.org
• Phone: 713-745-3837

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• IGFBP-2 vaccine after platinum to slow ovarian cancer recurrence

  This study tests whether giving an IGFBP-2 vaccine after one carboplatin dose can help prevent progression of ovarian, fallopian tube, or primary peritoneal cancer that has shown serologic recurrence.

  Recruiting Phase 2 University of Washington · Seattle, Washington · NCT07495124

• In-home cancer treatment with remote specialist support for patients in the Florida Panhandle

  This program will try giving standard cancer treatments at home to people living in the Florida Panhandle and nearby areas to see if they prefer it and have better treatment satisfaction.

  Recruiting Phase 2 Mayo Clinic · Jacksonville, Florida · NCT07285044

• Using cryocompression and cilostazol to prevent nerve damage from chemotherapy in women with gynecological cancers

  This study is testing if using cryocompression therapy alone or with a medication called cilostazol can help prevent nerve damage from chemotherapy in women with gynecological cancers.

  Recruiting Phase 2 Emory University · Atlanta, Georgia and 2 other locations · NCT06492070

• Treatment for recurrent ovarian cancer with HER2 expression

  This study is testing a new combination of treatments for women with recurrent ovarian cancer that has a specific protein called HER2 to see if it helps them feel better and live longer.

  Recruiting Phase 2 Peking University Cancer Hospital & Institute · Beijing, Beijing Municipality · NCT06420973

• Comparing stress reduction methods to standard care for ovarian cancer patients

  This study is testing if a mix of medications and therapies can help reduce stress in women with advanced ovarian cancer before their surgery, compared to those getting standard care.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT05429970

• Imaging with a new radioactive tracer for solid tumors

  This study is testing a new imaging method using a special radioactive tracer to see if it can help find tumor cells in patients with solid tumors like ovarian and breast cancers, while also looking at how safe it is and how it relates to certain genetic factors.

  Recruiting Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT03604315

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.